



February 18, 2021

Whom It May Concern

Company: KYORIN Holdings, Inc.  
Representative: Yutaka Ogihara  
Representative Director, President  
(Security Code: 4569, TSE 1st Sec.)  
Contact: Yoshinori Tanifuji  
Director, Corporate Planning  
Telephone: 03-3525-4707

NHI Drug Price Listing and Release of injectable New Quinolone Antibacterial Agent "Lasvic<sup>®</sup> Intravenous Drip Infusion Kit 150mg"

TOKYO, Japan (February 18, 2021) —KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Shigeru Ogihara), a wholly owned subsidiary of KYORIN Holdings, Inc., announced that the injectable new quinolone antibacterial drug Lasvic<sup>®</sup> Intravenous Drip Infusion Kit 150mg ("the Injection") which received approval from the Ministry of Health, Labor and Welfare in November 27, 2020 was listed on the National Health Insurance (NHI) drug price list today.

Through a domestic phase III clinical study in a double-blind comparative study for community-acquired pneumonia and an open-label, uncontrolled study for secondary infection of chronic respiratory disease and lung abscess, the effectiveness and safety of the Injection were evaluated and approved.

By adding the Injection to its product lineup in the respiratory tract infections, and providing up-to-date information continuously together with "Lasvic<sup>®</sup> Tablets 75 mg" released in January 2020, KYORIN Pharmaceutical Co.,Ltd. further contribute to the proper use of antibacterial agents and the treatment of patients. This contribution will also lead to the efforts against antimicrobial resistance (AMR) which has become a problem recently.

The release date of the Injection is scheduled on March 1, 2021 and sales for the first year are included in the consolidated forecast for the fiscal year ending March 31 2020 announced on November 5, 2020.

(Product Information)

Brand name	Lasvic® Intravenous Drip Infusion Kit 150mg
Generic name	Lascefloxacin Hydrochloride
INN	LSFX
Indications	<Bacterial strains> The genus <i>Staphylococcus</i> , the genus <i>Streptococcus</i> , <i>Streptococcus pneumoniae</i> , the genus <i>Enterococcus</i> , <i>Moraxella (Branhamella) catarrhalis</i> , <i>Escherichia coli</i> , the genus <i>Klebsiella</i> , the genus <i>Enterobacter</i> , <i>Haemophilus influenzae</i> , <i>Legionella pneumophila</i> , the genus <i>Peptostreptococcus</i> , the genus <i>Veillonella</i> , the genus <i>Bacteroides</i> , the genus <i>Prevotella</i> , the genus <i>Porphyromonas</i> , the genus <i>Fusobacterium</i> and <i>Mycoplasma pneumoniae</i> that are sensitive to this drug <Diseases> Pneumonia, lung abscess, secondary infection of chronic respiratory disease
Dosage and Administration	The usual dosage for adults is 300 mg of lascefloxacin on the first day of administration and 150 mg once daily on the second and subsequent days of administration.
NHI price	¥4,034
Date of approval of manufacturing and marketing	November 27, 2020
Date of Drug Price Listing	February 18, 2021
Date of Launch in Japan	March 1, 2021(estimated)
Manufacturer and seller	KYORIN Pharmaceutical Co., Ltd.

(Picture)

